$4.2 Billion is the total value of Cormorant Asset Management, LP's 105 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 100.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
OTLKW | Exit | OUTLOOK THERAPEUTICS INC*w exp 02/18/202 | $0 | – | -416,666 | -100.0% | -0.00% | – |
AMRN | Exit | AMARIN CORP PLCspons adr new | $0 | – | -300,000 | -100.0% | -0.05% | – |
KZR | Exit | KEZAR LIFE SCIENCES INC | $0 | – | -931,800 | -100.0% | -0.17% | – |
FIXX | Exit | HOMOLOGY MEDICINES INC | $0 | – | -470,897 | -100.0% | -0.19% | – |
SRNE | Exit | SORRENTO THERAPEUTICS INCcall | $0 | – | -500,000 | -100.0% | -0.21% | – |
AVEO | Exit | AVEO PHARMACEUTICALS INC | $0 | – | -1,000,000 | -100.0% | -0.23% | – |
CCXI | Exit | CHEMOCENTRYX INCcall | $0 | – | -250,000 | -100.0% | -0.53% | – |
GLPG | Exit | GALAPAGOS NVspon adr | $0 | – | -130,000 | -100.0% | -0.71% | – |
ARCT | Exit | ARCTURUS THERAPEUTICS HLDGS | $0 | – | -700,000 | -100.0% | -1.16% | – |
Exit | TRILLIUM THERAPEUTICS INC | $0 | – | -2,500,000 | -100.0% | -1.37% | – | |
EIDX | Exit | EIDOS THERAPEUTICS INC | $0 | – | -993,185 | -100.0% | -1.93% | – |
MYOK | Exit | MYOKARDIA INC | $0 | – | -450,000 | -100.0% | -2.36% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
OMEROS CORP | 27 | Q3 2021 | 6.5% |
MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
SC 13G | 2024-05-13 |
4 | 2024-05-08 |
SC 13G | 2024-04-29 |
4 | 2024-04-22 |
SC 13G/A | 2024-04-15 |
4 | 2024-04-03 |
SC 13G | 2024-03-21 |
4 | 2024-03-18 |
SC 13G/A | 2024-03-18 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.